TENKASI

This brand name is authorized in Austria, Croatia, Estonia, Finland, France, Ireland, Italy, Lithuania, Poland, UK.

Active ingredients

The drug TENKASI contains one active pharmaceutical ingredient (API):

1	Oritavancin UNII PUG62FRZ2E - ORITAVANCIN
	Oritavancin is used for the treatment of patients with acute bacterial skin and skin structure infections (ABSSSI).
	Read more about Oritavancin

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
TENKASI Powder for solution for infusion	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
J01XA05		J Antiinfectives for systemic use → J01 Antibacterials for systemic use → J01X Other antibacterials → J01XA Glycopeptide antibacterials
Discover more medicines within J01XA05

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1680960, 3044113
FI	Lääkealan turvallisuus- ja kehittämiskeskus	433794
FR	Base de données publique des médicaments	67623773, 68529070
IT	Agenzia del Farmaco	044015016, 044015028
LT	Valstybinė vaistų kontrolės tarnyba	1076035
PL	Rejestru Produktów Leczniczych	100342536